NYSE:MRX Medicis Pharmaceutical (MRX) Stock Price, News & Analysis → Only a fool would buy Nvidia today… (From Porter & Company) (Ad) Free MRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Medicis Pharmaceutical alerts: Email Address Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> About Medicis Pharmaceutical Stock (NYSE:MRX)Medicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).Read More Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> MRX Stock News HeadlinesDecember 20, 2023 | seekingalpha.comTLPPF Telix Pharmaceuticals LimitedDecember 5, 2023 | finance.yahoo.comPrime Therapeutics announces Ken Bodmer as chief financial officerMarch 28, 2024 | Porter & Company (Ad)Only a fool would buy Nvidia today… Average people are too busy throwing their money into Nvidia, Google, and every other overvalued tech firm… while missing what could be the biggest story of the decade.November 1, 2023 | morningstar.comAcelRx Pharmaceuticals Inc ACRXOctober 5, 2023 | finance.yahoo.comPRIME THERAPEUTICS/MAGELLAN RX EXPANDS PARTNERSHIP WITH MHK TO MANAGE MEMBER ENROLLMENT WITH MARKETPROMINENCE TECHNOLOGYMarch 27, 2023 | uk.finance.yahoo.comAnanda Developments Plc - Result of General MeetingMarch 23, 2023 | bizjournals.comBoston Pharmaceuticals NewsMarch 9, 2023 | finanznachrichten.deAnanda Developments Plc - Acquisition of MRX and SubscriptionMarch 28, 2024 | Porter & Company (Ad)Only a fool would buy Nvidia today… Average people are too busy throwing their money into Nvidia, Google, and every other overvalued tech firm… while missing what could be the biggest story of the decade.September 20, 2022 | markets.businessinsider.comXpira Pharmaceuticals Inc. Receives FDA Approval For Psilocybin Trial IND ApplicationAugust 31, 2022 | thestreet.comMedicis to Acquire InamedJanuary 22, 2022 | thestreet.comMedicis Stock Hits New 52-Week High (MRX)January 5, 2022 | investing.comMedicis Pharmaceutical Corp (MRX)See More Headlines Receive MRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicis Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNYSE:MRX CUSIPN/A CIK859368 Webwww.Medicis.com Phone+1-212-5992000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesRobert Roswell Chai-Onn (Age 44)Executive Vice President, General Counsel, Secretary, Director Howard Bradley Schiller (Age 53)Officer, Director Ryan WeldonOfficer, Director This page (NYSE:MRX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceFed launches fourth dollar overhaulStansberry Research“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicis Pharmaceutical Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.